For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development expenses | 6,673 | 10,631 | ||
| General and administrative expenses | 928,114 | 628,233 | ||
| Total operating expenses | 934,787 | 638,864 | ||
| Loss from operations | -934,787 | -638,864 | ||
| Interest income (expense), net | -36,069 | -36,067 | ||
| Total other expenses | -36,069 | -36,067 | ||
| Loss from continued operations | -970,856 | -674,931 | ||
| Net loss from continued operations | -970,856 | -674,931 | ||
| Loss from discontinued operations net of tax | -181,953 | -323,340 | ||
| Net loss | -1,152,809 | -998,271 | ||
| Preferred stock dividends | 90,745 | 82,165 | ||
| Net loss applicable to common shareholders | -1,243,554 | -1,080,436 | ||
| Basic EPS | -0.75 | -0.21 | ||
| Diluted EPS | -0.75 | -0.21 | ||
| Basic Average Shares | 1,652,679 | 4,765,004 | ||
| Diluted Average Shares | 1,652,679 | 4,765,004 | ||
Entero Therapeutics, Inc. (ENTO)
Entero Therapeutics, Inc. (ENTO)